DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65

DexCom, Inc. announced the publication of its CONNECT study in The New England Journal of Medicine, marking the first clinical data on standalone real-time continuous glucose monitoring (CGM) technology published in nearly two decades. The randomized controlled trial demonstrated that the Dexcom G7 significantly reduces A1C levels and improves glucose control compared to routine care, with benefits observed across a diverse participant group, including those over 65 and those taking GLP-1 medications. This study supports the earlier use of CGM in Type 2 diabetes care.